The Temple City, California-based NGS genetic testing firm more than doubled its number of billable tests compared to the prior-year period.
A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
CMS has attempted to address stakeholders' concerns about its coverage criteria for germline NGS testing in a new proposed national policy.
Negative results in recent trials have highlighted the challenges that newer genomic test makers must overcome in proving methods for personalized CUP treatment.
Illumina officials discussed several issues with investors, including the new Qiagen partnership, while at ASHG the firm introduced reagent kit upgrades.
Overall growth was driven by growth in sequencing instrument and consumables sales, which offset a 24 percent decline in microarray revenues.
The company launched a "core" service using Illumina microarray genotyping, and has plans for an expanded NGS offering with Quest Diagnostics.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.
The early-stage genomics-based trials suggest tumor sequence can be informative for late-stage cancers, as an ESMO group seeks clinically meaningful translation.
A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.
The firm disclosed to the state of California that it plans to lay off 42 employees in San Diego and 16 employees in Foster City.
Euformatics, EMQN, and GenQA will extend prior work on the development of an external quality assessment technical scheme for NGS-based clinical testing.
A report from the NSIGHT2 trial compares the diagnostic and analytical performance of clinical whole-genome and exome sequencing on an infant cohort.
The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.
Under the agreement, the companies plan to offer combined genetic and biochemical testing services out of Blueprint's clinical laboratory in Seattle.
Seattle-based Adaptive will develop in vitro diagnostic test kits for distribution, which will run on Illumina's NextSeq 550 Dx system.
The industry organization issued a letter urging the agency to reconsider recent decisions to demand several laboratories stop offering pharmacogenetic testing.
The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
Researchers are sampling the wild relatives of modern crops to try to preserve genetic diversity, NPR reports.
MIT's Search for Extraterrestrial Genomes is developing sequencing tools to use to try to detect whether there is any life on Mars, Quartz reports.
Undark reports on a bill introduced this year to the US House of Representatives to strengthen scientific integrity.
In Genome Research this week: post-zygotic mutations in diabetes development, single-cell RNA sequencing study of aging, and more.